# Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

> **NCT01650090** · PHASE2 · COMPLETED · sponsor: **Eleison Pharmaceuticals LLC.** · enrollment: 28 (actual)

## Conditions studied

- Pulmonary Relapse of Osteosarcoma

## Interventions

- **DRUG:** Inhaled Lipid Cisplatin (ILC)

## Key facts

- **NCT ID:** NCT01650090
- **Lead sponsor:** Eleison Pharmaceuticals LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650090, "Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01650090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*